Global Genetic Toxicology Testing Market Report 2024

The genetic toxicology testing market size has grown rapidly in recent years. It will grow from $1.48 billion in 2023 to $1.63 billion in 2024 at a compound annual growth rate (CAGR) of 10%. The growth observed in the historical period can be attributed to several key factors, including escalating public health crises, the impact of increasing globalization, heightened emphasis on personalized medicine, growing demand for robust testing solutions, and a rising number of pharmaceutical drugs entering the market.

The genetic toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $2.4 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the forecast period can be attributed to several factors, including an increased demand for testing novel foods, growing concerns regarding potential risks associated with various substances, heightened environmental and health awareness, escalating regulatory scrutiny, the expanded utilization of in vitro testing methods, and the emergence of high-throughput screening platforms. Key trends expected in the forecast period encompass advancements in precision medicine and toxicogenomics, comprehensive risk communication strategies, developments in genetic toxicology testing methodologies, progress in risk assessment methodologies, the integration of omics technologies into testing protocols, and advancements in genomics and molecular biology techniques.

The surge in demand for personalized medicine is anticipated to drive the expansion of the genetic toxicology testing market in the coming years. Personalized medicine, a healthcare approach that tailors interventions and products to individual patients based on their predicted response or disease risk, has gained traction due to genetic advancements, improved disease understanding, biomarker-based diagnostics availability, value-based healthcare initiatives, and integration into clinical practice and research. Genetic toxicology testing plays a vital role in personalized medicine by furnishing crucial insights into genetic variability, susceptibility to genotoxic agents, and treatment response. For instance, as reported by the Personalized Medicine Coalition in February 2024, the FDA greenlit 16 new personalized medicines for rare disease patients in 2023, a significant increase from six in 2022. Thus, the growing demand for personalized medicine serves as a catalyst for the genetic toxicology testing market.

Major players in the genetic toxicology testing market are concentrating on developing innovative drug screening platforms such as phenotypic drug screening to enhance accuracy and efficiency in identifying potential genetic toxins. Phenotypic drug screening involves testing compounds based on their capacity to elicit a specific cellular or physiological response in a whole organism or relevant cell system. For example, in August 2022, Creative Biogene, a US-based biotechnology company, unveiled zebrafish disease models tailored to support drug discovery and toxicology research. These models replicate human genetic diseases in zebrafish, offering insights into disease mechanisms, drug discovery, and toxicology. Creative Biogene's zebrafish models serve as a valuable tool for evaluating drug toxicity, predicting the safety of novel compounds, and bolstering the drug development pipeline.

In June 2021, Charles River Laboratories International Inc., a US-based chemical manufacturer, completed the acquisition of Vigene Biosciences for approximately $292.5 million in cash. This strategic move aims to bolster Charles River Laboratories' gene therapy capabilities in the burgeoning cell and gene therapy contract development and manufacturing organization (CDMO) sectors. Vigene Biosciences Inc., headquartered in the US, specializes in viral vector-based gene delivery technologies for life science research, gene therapy, and cell therapy applications, offering genetic toxicology testing services as part of its CDMO offerings.

Major companies operating in the genetic toxicology testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, SGS SA, WuXi AppTec, Intertek Group plc, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Fraunhofer ITEM, Jubilant Life Sciences Limited, Evotec SE, Inotiv Inc., Promega Corporation, Syngene International Limited, Nelson Laboratories LLC, Instem, Frontage Laboratories Inc., Creative Bioarray, Creative Biolabs Inc., Gentronix Limited, MB Research Laboratories.

North America was the largest region in the genetic toxicology testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic toxicology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Genetic toxicology testing is a specialized field within toxicology dedicated to assessing the potential of chemical substances to cause damage to genetic material, including DNA, RNA, and chromosomes. Its primary objective is to determine the genotoxicity of compounds and identify any adverse effects they may have on the genetic material of living organisms, including humans. This testing serves as a crucial tool for evaluating the safety of pharmaceuticals, chemicals, and environmental pollutants, particularly concerning genotoxic hazards.

The primary classifications within the genetic toxicology testing market include in vitro and in vivo methodologies. In vitro testing refers to experiments or studies conducted in a controlled laboratory environment, such as test tubes, petri dishes, or other artificial settings, without the involvement of living organisms. Various products encompass services, reagents, consumables, and assays, utilized across diverse applications spanning the healthcare, food, cosmetics, agriculture industries, among others.

The genetic toxicology testing market research report is one of a series of new reports that provides genetic toxicology testing market statistics, including the genetic toxicology testing industry's global market size, regional shares, competitors with a genetic toxicology testing market share, detailed genetic toxicology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the genetic toxicology testing industry. This genetic toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genetic toxicology testing market includes revenues earned by entities through mutagenicity testing, genotoxicity screening, carcinogenicity testing, regulatory compliance, risk assessment, bacterial mutation assays, comet assays, micronucleus tests, presymptomatic testing, ancestry testing, and nutrigenomics testing, and related cell culture systems, assay kits, microscopes, flow cytometers, automation and robotics, and flow cytometry. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.